IVVD · Invivyd, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Based on current operating plans and excluding future external financing, the Company will not have sufficient cash and cash equivalents to fund its operating expenses and capital requirements beyond one year from the issuance of these condensed consolidated financial statements, and therefore, the Company has concluded that there is substantial doubt about its ability to continue as a going concern.”View the 10-Q filed May 14, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-05-19 | MCGUIRE TERRANCE |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option was granted on May 19, 2026 and vests in full upon the earlier of (i) May 19, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date. |
Stock Option (Right to Buy)
|
50,000 |
| 2026-05-19 | BOLNO PAUL |
Director, President and CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option was granted on May 19, 2026 and vests in full upon the earlier of (i) May 19, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date. |
Stock Option (Right to Buy)
|
32,876 |
| 2026-05-19 | Berry Tamsin |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option was granted on May 19, 2026 and vests in full upon the earlier of (i) May 19, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date. |
Stock Option (Right to Buy)
|
50,000 |
| 2026-05-19 | MCLAUGHLIN KEVIN F |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option was granted on May 19, 2026 and vests in full upon the earlier of (i) May 19, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date. |
Stock Option (Right to Buy)
|
50,000 |
| 2026-05-19 | Elia Marc |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option was granted on May 19, 2026 and vests in full upon the earlier of (i) May 19, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date. The grant was awarded to Marc Elia ("Mr. Elia"). Mr. Elia is deemed to hold the grant for the benefit of M28 Capital Management LP ("M28 Capital Management") and the funds managed by M28 Capital Management. |
Stock Option (Right to Buy)
|
50,000 |
| 2026-05-19 | Royan Ajay |
Director, 10% Owner |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option was granted on May 19, 2026 and vests in full upon the earlier of (i) May 19, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date. |
Stock Option (Right to Buy)
|
50,000 |
| 2026-02-18 | Lee Timothy Edward |
Chief Commercial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary "sell-to-cover" transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.550 to $1.595, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. |
Common Stock
|
20,964 |
| 2026-02-18 | Green Julie |
Chief Human Resources Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary "sell-to-cover" transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.550 to $1.595, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. |
Common Stock
|
20,964 |
| 2026-02-18 | Duke William E. |
Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary "sell-to-cover" transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.550 to $1.595, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. |
Common Stock
|
20,964 |
| 2026-02-18 | Andersen Jill |
Chief Legal Officer, Secretary |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary "sell-to-cover" transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.550 to $1.595, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. |
Common Stock
|
34,939 |
| 2026-02-18 | Allen Robert D. III |
Chief Scientific Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary "sell-to-cover" transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.550 to $1.595, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. |
Common Stock
|
19,392 |
| 2026-02-17 | Allen Robert D. III |
Chief Scientific Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary "sell-to-cover" transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.505 to $1.590, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. |
Common Stock
|
18,189 |
| 2026-02-17 | Andersen Jill |
Chief Legal Officer, Secretary |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary "sell-to-cover" transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.505 to $1.590, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. |
Common Stock
|
32,771 |
| 2026-02-17 | Duke William E. |
Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary "sell-to-cover" transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.505 to $1.590, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. |
Common Stock
|
19,663 |
| 2026-02-17 | Green Julie |
Chief Human Resources Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary "sell-to-cover" transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.505 to $1.590, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. |
Common Stock
|
19,663 |
| 2026-02-17 | Lee Timothy Edward |
Chief Commercial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary "sell-to-cover" transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.505 to $1.590, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. |
Common Stock
|
19,663 |
| 2026-02-15 | Duke William E. |
Chief Financial Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Invivyd, Inc. (the "Company"). |
Common Stock
|
99,000 |
| 2026-02-15 | Lee Timothy Edward |
Chief Commercial Officer |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Invivyd, Inc. (the "Company"). This RSU award vests over an eighteen-month period, with one-third of the RSUs vesting every six months following the grant date of February 15, 2025, subject to the Reporting Person's continuous service as of each vesting date. |
Restricted Stock Units
|
99,000 |
| 2026-02-15 | Allen Robert D. III |
Chief Scientific Officer |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Invivyd, Inc. (the "Company"). This RSU award vests over an eighteen-month period, with one-third of the RSUs vesting every six months following the grant date of February 15, 2025, subject to the Reporting Person's continuous service as of each vesting date. |
Restricted Stock Units
|
99,000 |
| 2026-02-15 | Andersen Jill |
Chief Legal Officer, Secretary |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Invivyd, Inc. (the "Company"). This RSU award vests over an eighteen-month period, with one-third of the RSUs vesting every six months following the grant date of February 15, 2025, subject to the Reporting Person's continuous service as of each vesting date. |
Restricted Stock Units
|
165,000 |
| 2026-02-15 | Green Julie |
Chief Human Resources Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Invivyd, Inc. (the "Company"). |
Common Stock
|
99,000 |
| 2026-02-15 | Allen Robert D. III |
Chief Scientific Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Invivyd, Inc. (the "Company"). |
Common Stock
|
99,000 |
| 2026-02-15 | Duke William E. |
Chief Financial Officer |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Invivyd, Inc. (the "Company"). This RSU award vests over an eighteen-month period, with one-third of the RSUs vesting every six months following the grant date of February 15, 2025, subject to the Reporting Person's continuous service as of each vesting date. |
Restricted Stock Units
|
99,000 |
| 2026-02-15 | Green Julie |
Chief Human Resources Officer |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Invivyd, Inc. (the "Company"). This RSU award vests over an eighteen-month period, with one-third of the RSUs vesting every six months following the grant date of February 15, 2025, subject to the Reporting Person's continuous service as of each vesting date. |
Restricted Stock Units
|
99,000 |
| 2026-02-15 | Lee Timothy Edward |
Chief Commercial Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Invivyd, Inc. (the "Company"). The reported ownership includes 10,000 shares of common stock acquired through the Company's Employee Stock Purchase Program. |
Common Stock
|
99,000 |
| 2026-02-15 | Andersen Jill |
Chief Legal Officer, Secretary |
Convert↑
Filing footnotes — Common Stock (Direct)
Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Invivyd, Inc. (the "Company"). |
Common Stock
|
165,000 |
| 2026-01-29 | Lee Timothy Edward |
Chief Commercial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option vests over a three-year period, with 1/36th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date of January 29, 2026, subject to the Reporting Person's continuous service as of each vesting date. |
Stock Option (Right to Buy)
|
675,000 |
| 2026-01-29 | Allen Robert D. III |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option vests over a three-year period, with 1/36th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date of January 29, 2026, subject to the Reporting Person's continuous service as of each vesting date. |
Stock Option (Right to Buy)
|
625,000 |
| 2026-01-29 | Andersen Jill |
Chief Legal Officer, Secretary |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option vests over a three-year period, with 1/36th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date of January 29, 2026, subject to the Reporting Person's continuous service as of each vesting date. |
Stock Option (Right to Buy)
|
820,000 |
| 2026-01-29 | Duke William E. |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option vests over a three-year period, with 1/36th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date of January 29, 2026, subject to the Reporting Person's continuous service as of each vesting date. |
Stock Option (Right to Buy)
|
625,000 |
| 2026-01-29 | Green Julie |
Chief Human Resources Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option vests over a three-year period, with 1/36th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date of January 29, 2026, subject to the Reporting Person's continuous service as of each vesting date. |
Stock Option (Right to Buy)
|
675,000 |
| 2025-11-19 | MCLAUGHLIN KEVIN F |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock acquired in an underwritten public offering. |
Common Stock
|
50,000 |
| 2025-09-22 | BOLNO PAUL |
Director, President and CEO |
Other↑
|
No Securities Owned
|
0 |
| 2025-09-22 | BOLNO PAUL |
Director, President and CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option was granted on September 22, 2025 and vests over a three-year period, with one-third of the shares subject to the grant vesting on the first anniversary of the grant date and 1/36th of the total shares subject to the grant vesting in substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date. |
Stock Option (Right to Buy)
|
100,000 |
| 2025-08-19 | Andersen Jill |
Chief Legal Officer, Secretary |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary "sell-to-cover" transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.5524 to $0.6040, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. |
Common Stock
|
49,402 |
| 2025-08-19 | Lee Timothy Edward |
Chief Commercial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary "sell-to-cover" transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.5524 to $0.6040, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. |
Common Stock
|
29,643 |
| 2025-08-19 | Duke William E. |
Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary "sell-to-cover" transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.5524 to $0.6040, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. |
Common Stock
|
29,643 |
| 2025-08-19 | Green Julie |
Chief Human Resources Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary "sell-to-cover" transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.5524 to $0.6040, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. |
Common Stock
|
29,643 |
| 2025-08-19 | Allen Robert D. III |
Chief Scientific Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary "sell-to-cover" transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.5524 to $0.6040, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. |
Common Stock
|
27,420 |
| 2025-08-18 | Lee Timothy Edward |
Chief Commercial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary "sell-to-cover" transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.5801 to $0.7134, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. |
Common Stock
|
20,013 |
| 2025-08-18 | Allen Robert D. III |
Chief Scientific Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary "sell-to-cover" transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.5801 to $0.7134, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. |
Common Stock
|
18,512 |
| 2025-08-18 | Duke William E. |
Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary "sell-to-cover" transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.5801 to $0.7134, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. |
Common Stock
|
20,013 |
| 2025-08-18 | Andersen Jill |
Chief Legal Officer, Secretary |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary "sell-to-cover" transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.5801 to $0.7134, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. |
Common Stock
|
33,352 |
| 2025-08-18 | Green Julie |
Chief Human Resources Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary "sell-to-cover" transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.5801 to $0.7134, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. |
Common Stock
|
20,013 |
| 2025-08-15 | Green Julie |
Chief Human Resources Officer |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Invivyd, Inc. (the "Company"). This RSU award vests over an eighteen-month period, with one-third of the RSUs vesting every six months following the grant date of February 15, 2025, subject to the Reporting Person's continuous service as of each vesting date. |
Restricted Stock Units
|
99,000 |
| 2025-08-15 | Allen Robert D. III |
Chief Scientific Officer |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Invivyd, Inc. (the "Company"). This RSU award vests over an eighteen-month period, with one-third of the RSUs vesting every six months following the grant date of February 15, 2025, subject to the Reporting Person's continuous service as of each vesting date. |
Restricted Stock Units
|
99,000 |
| 2025-08-15 | Lee Timothy Edward |
Chief Commercial Officer |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Invivyd, Inc. (the "Company"). This RSU award vests over an eighteen-month period, with one-third of the RSUs vesting every six months following the grant date of February 15, 2025, subject to the Reporting Person's continuous service as of each vesting date. |
Restricted Stock Units
|
99,000 |
| 2025-08-15 | Allen Robert D. III |
Chief Scientific Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Invivyd, Inc. (the "Company"). |
Common Stock
|
99,000 |
| 2025-08-15 | Duke William E. |
Chief Financial Officer |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Invivyd, Inc. (the "Company"). This RSU award vests over an eighteen-month period, with one-third of the RSUs vesting every six months following the grant date of February 15, 2025, subject to the Reporting Person's continuous service as of each vesting date. |
Restricted Stock Units
|
99,000 |
| 2025-08-15 | Andersen Jill |
Chief Legal Officer, Secretary |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Invivyd, Inc. (the "Company"). This RSU award vests over an eighteen-month period, with one-third of the RSUs vesting every six months following the grant date of February 15, 2025, subject to the Reporting Person's continuous service as of each vesting date. |
Restricted Stock Units
|
165,000 |